Clinical trials: HIV-Associated Lipodystrophy Syndrome
HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
This is a prospective, non-randomised, 48 week study of the effect of protease inhibitor (PI) containing and non-PI containing antiretroviral regimens on the expression of adipocyte specific genes, protein levels and cellular…
- Trial name
- NCT00192660
- Testing
- Lamivudine, Stavudine, Didanosine
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
HIV
Eplerenone in HIV Associated Abdominal Fat Accumulation
The purpose of this study is to test the effects of a drug, eplerenone, along with lifestyle modification to affect sugar metabolism, body fat distribution, and cardiovascular health in HIV-infected individuals.
- Trial name
- NCT01405456
- Testing
- Eplerenone and lifestyle
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
HIV-associated Lipodystrophy Syndrome
An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects
This will be a two-part study in healthy adults. Part A is a phase 1, non-randomized, open label, single-dose, single-centre mass balance study utilizing a radiolabeled dose to investigate the recovery, excretion, and…
- Trial name
- NCT01848340
- Testing
- GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Associated Lipodystrophy Syndrome., HIV
Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV infected individuals. However an increasing number of HIV-patients have developed metabolic and morphological alterations including…
- Conditions
- HIV Associated Lipodystrophy Syndrome., HIV, Hypercholesterolemia, Lipoatrophy
- Trial name
- NCT00139178
- Testing
- Different HAART regimens
- Where
- 4 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Danish HIV Research Group
HIV-Associated Lipodystrophy Syndrome, HIV Infections
Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients
The aim of this randomized study is to compare the effect of pioglitazone versus placebo on change in limb fat in HIV 1-infected patients treated with antiretroviral therapy for at least 6 months and with clinical lipoatrophy.
- Trial name
- NCT00148850
- Testing
- Pioglitazone
- Where
- France
- Volunteers
- 130 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections, Lipodystrophy
Therapeutic Approaches to HAART-Induced Lipodystrophy
To determine the efficacy and safety of 4 therapeutic interventions on HAART-Induced lipodystrophy. The interventions are: 1) Dietary - the effect of a high carbohydrate vs.a high cis-monounsaturated fatty acid diet.
- Trial name
- NCT00461552
- Testing
- Leptin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Texas Southwestern Medical Center
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency
Body Composition and Adipose Tissue in HIV
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity.
- Conditions
- HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
- Trial name
- NCT03226821
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the…
- Conditions
- HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X
- Trial name
- NCT00130286
- Testing
- Rosiglitazone, Recombinant human growth hormone + rosiglitazone
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- Weill Medical College of Cornell University
HIV-Associated Lipodystrophy Syndrome
Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome
The hypotheses of this study were that: 1. HIV lipodystrophy is associated with psychological morbidity relating to body image, anxiety and depression. 2.
- Trial name
- NCT01359917
- Volunteers
- 50 people
- Sponsor
- NHS Lothian
HIV Infections, HIV Lipodystrophy Syndrome
Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy
The aim of this trial is to evaluate the impact on fat distribution of switching to NRTI-sparing regimens in lipoatrophic antiretroviral experienced patients with complete viral suppression.
- Trial name
- NCT00122655
- Testing
- non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitors
- Where
- France
- Volunteers
- 100 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV/AIDS, HIV Lipodystrophy Syndrome
Energy Expenditure of People Living With HIV/AIDS
Background: Several studies have reported increased resting energy expenditure (REE) in people living with HIV/AIDS possibly due to changes in body composition that occurs in HIV lipodystrophy syndrome.
- Trial name
- NCT02530827
- Testing
- use of lipid-lowering drugs.
- Volunteers
- 45 people
- Sponsor
- University of Sao Paulo General Hospital
Insulin Resistance, Cardiovascular Diseases
Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV
The purpose of this study is to test whether chronic administration of the drug acipimox will improve hyperlipidemia and insulin sensitivity among HIV infected patients experiencing highly active antiretroviral therapy (HAART)…
- Conditions
- Insulin Resistance, Cardiovascular Diseases, Heart Diseases, HIV Infections
- Trial name
- NCT00246402
- Testing
- Acipimox
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
HIV Infections, Lipodystrophy
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-associated Adipose Redistribution Syndrome…
- Trial name
- NCT00082628
- Testing
- Serostim® 4 mg, Serostim® 2 mg
- Where
- 31 sites in United States, Canada
- Volunteers
- 326 people
- Sponsor
- EMD Serono
HIV Infections, Lipodystrophy
TH9507 in Patients With HIV-Associated Lipodystrophy
HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation and loss of extremity and subcutaneous fat, in…
- Trial name
- NCT00123253
- Testing
- TH9507
- Where
- 42 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Theratechnologies
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy
Evaluation of Albuminuria HIV-Infected Patients
This study will examine the following: 1) how common albuminuria and proteinuria are among HIV-positive patients, 2) what causes albuminuria or proteinuria in these patients and 3) whether the condition becomes more severe over…
- Conditions
- HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria
- Trial name
- NCT00524992
- Where
- 2 sites in United States
- Volunteers
- 252 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV-Associated Lipodystrophy, HIV Infections
Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy
This is a multi-centre, open-label, 96 week study to evaluate the safety, tolerability and extent and duration of improvement in HIV-1 infected subjects with antiretroviral induced facial lipoatrophy, randomised in a 1:1 ratio to…
- Trial name
- NCT00126308
- Testing
- poly-L-lactic acid
- Where
- 18 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Kirby Institute
HIV Facial Lipoatrophy
Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy
The purpose of this study is to test the safety of Voluma and see what effects it has on HIV facial lipoatrophy. The hypothesis is that Voluma will be safe, efficacious and positively impact the quality-of-life in the treatment…
- Trial name
- NCT02342223
- Testing
- Voluma
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jared Jagdeo, MD, MS
HIV Infections, HIV-Associated Lipodystrophy Syndrome
MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)
This is a randomized prospective study into metabolic adverse events during different types of initial antiretroviral therapy in HIV-1-infected men.
- Trial name
- NCT00122226
- Testing
- Lopinavir/ritonavir + zidovudine + lamivudine, Lopinavir/ritonavir + nevirapine
- Where
- 13 sites in Finland, Netherlands and 2 more
- Volunteers
- 50 people
- Sponsor
- Amsterdam UMC, location VUmc
Lipodystrophy Syndrome, HIV, Sarcopenia
Detraining in People Living With HIV/AIDS
The goal of this study was to evaluate the effect of detraining in the components of physical aptitude of people living with HIV/Aids (PVHA).
- Trial name
- PVHA (NCT03075332)
- Testing
- combined training
- Where
- 2 sites in Brazil
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
HIV-Associated Lipodystrophy Syndrome
Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome
The purpose of this clinical research study is to learn if human immunodeficiency virus (HIV)-infected subjects with abdominal fat accumulation on their highly active antiretroviral treatment (HAART) regimen have better changes…
- Trial name
- NCT00135356
- Testing
- Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs), continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 219 people
- Sponsor
- Bristol-Myers Squibb